Mtbvac Tuberculosis Vaccine

On 24th March, Bharat Biotech commenced clinical trials for Mtbvac, the first TB vaccine derived from a human source.

Mtbvac developed for improved efficacy over BCG in newborns and prevention in adults.
Trials conducted in collaboration with Biofabri; pivotal trial planned for 2025.
India, with a high TB burden, crucial for testing adult and adolescent vaccines.
Mtbvac marks significant progress in the quest for a more effective TB vaccine.
Phase-3 clinical trials comparing Mtbvac with BCG initiated in newborns.